COVID-19 in hospitalized adults and pediatric patients two years of age or older requiring supplemental oxygen, invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO).DOWNLOAD: The FOX 5 DC News app for local breaking news and weatherIn a clinical trial of hospitalized patients with COVID-19, baricitinib, in combination with remdesivir, was shown to reduce time to recovery within 29 days after initiating treatment compared to patients who received a placebo with remdesivir.The safety and effectiveness of this investigational therapy for use in the treatment of COVID-19 continues to be evaluated.